Immunotherapy, gene editing advances extend to Type 1 Diabetes

December 13, 2017, Seattle Children's Research Institute
Dr. Jane Buckner of the Benaroya Research Institute at Virginia Mason and Dr. David Rawlings at Seattle Children's Research Institute are leading research to develop an immunotherapy for type 1 diabetes. Credit: Seattle Children's

Advances in engineering T cells to treat cancer are paving the way for new immunotherapies targeted at autoimmune diseases, including type 1 diabetes. Now, researchers are also investigating therapies that reprogram T cells to "turn down" an immune response, which may hold promise for curing type 1 diabetes, as well as a number of diseases where overactive T cells attack a person's healthy cells and organs.

"Instead of stimulating the immune system to seek and destroy , treating autoimmune conditions will require programming a patient's own T cells to tell rogue immune cells to calm down," said Dr. David Rawlings, director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute and chief of the Division of Immunology at Seattle Children's Hospital.

Harnessing gene-editing techniques pioneered by Seattle Children's, Rawlings and colleagues have already made headway in equipping T cells with the instructions needed to potentially reverse type 1 . In a new $2 million research project funded by The Leona M. and Harry B. Helmsley Charitable Trust, researchers will leverage these recent successes using this new form of T-cell immunotherapy into first-in-human clinical trials.

Developing a type 1 diabetes immunotherapy

The new research continues the collaboration with Benaroya Research Institute at Virginia Mason, building on significant progress the joint research teams made after receiving a $1 million grant from the Helmsley Charitable Trust in 2016.

In their initial studies, the scientists succeeded in using gene editing to generate human T cells that function as regulatory cells, a type of immune cell that moderates the immune system's response. These engineered regulatory T cells were capable of turning off "dangerous" effector T cells both in the laboratory and in animal studies. In parallel, the researchers were able to isolate T cells that recognized a specific 'antigen' target, and turn these antigen-specific effector cells into regulatory T cells.

Their new studies are designed to single out the dangerous effector T cells that malfunction and attack the pancreas in type 1 diabetes, preventing the production of insulin, and turn them into regulatory T cells.

"These engineered regulatory T cells, when returned to a diabetic's body, would have the potential to stop effector T cells from destroying the insulin-producing cells," said Rawlings. "We believe these cells could be used to treat type 1 diabetes as it begins, possibly leading to a long-term cure."

The next phase of research will continue to draw on the extensive expertise of Dr. Jane Buckner, president of Benaroya Research Institute, and her colleagues to isolate and target the immune cells of the pancreas.

"The benefit of using regulatory T cells for therapy is that the T cells can focus immune suppression to a specific organ without impairing the entire immune system," said Buckner. "For type 1 diabetes, we want to ensure the engineered T cells travel to the pancreas and stop any T-cell attacks in the pancreas, leaving healthy untouched."

A new treatment to replace insulin injections

It's Rawlings' and Buckner's hope that this research will lead to new treatments to improve the lives of those battling type 1 diabetes. They believe a clinical trial offering a T-cell immunotherapy product for type 1 diabetes patients is on the horizon.

"The ultimate goal of this research is to bring an engineered regulatory T-cell immunotherapy to patients," said Rawlings.

An immunotherapy delivered through an infusion of engineered regulatory T cells might protect new patients that are developing type 1 diabetes from the life-long requirement for insulin therapy.

Type 1 diabetes patients like 13-year-old Juliana Graceffo must take carefully calculated doses of insulin throughout the day to maintain their ideal blood sugar levels. Giving patients insulin - either through injections or an insulin pump - is currently the only treatment for type 1 diabetes. As patients are often diagnosed with type 1 diabetes in childhood, managing and treating their diabetes becomes a way of life and if control is not maintained, fluctuations in blood sugar lead to chronic damage to organs over time.

"It's hard dealing with type 1 diabetes every day," said Juliana. "A cure would mean that I don't have to think about diabetes all the time, and I can just be normal."

Beyond diabetes

The type 1 diabetes immunotherapy is one of many promising cell and gene therapies in development at Seattle Children's.

In the lab, Rawlings has pioneered a groundbreaking gene editing technique that gives T cells the ability to resist HIV infection and simultaneously kill HIV-infected T cells or B-cell tumors. Most recently, with his colleague Dr. Richard James, they used gene editing to generate B cells that secrete therapeutic proteins.

Gene editing is poised to impact pediatric medicine on many fronts and is now being applied by researchers working to cure cancer, autoimmune diseases and genetic disorders such as severe combined immune deficiency and sickle cell disease. To move this work forward more rapidly, Rawlings' team is also partnering with a gene-editing industry-leader, Casebia Therapeutics, to develop and license new therapies to prevent and treat autoimmune disease using CRISPR/Cas9 gene-edited regulatory T .

"Knowledge gained through our work with Casebia is likely to extend to type 1 diabetes, organ transplant, other autoimmune conditions and genetic diseases," said Rawlings. "We're excited to continue to advance this promising research."

Explore further: Video: Expert discusses the cause of diabetes

Related Stories

Video: Expert discusses the cause of diabetes

November 17, 2017
The numbers are staggering: 30.3 million Americans—350 million people worldwide—live with diabetes, according to the Centers for Disease Control. Nearly 1 in 4 Americans don't know they have it. U.S. health care costs ...

Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017
Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) ...

'Educating' patients' immune cells may help combat diabetes

July 7, 2017
New research reveals that a treatment called Stem Cell Educator therapy is safe and effective for treating type 1 and type 2 diabetes. The therapy cultures the patient's immune cells with cord blood stem cells and returns ...

Scientists study how some insulin-producing cells survive in type 1 diabetes

February 9, 2017
A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in ...

Could modifying gut microbes prevent or delay type 1 diabetes?

September 12, 2017
Autoimmune diseases such as type 1 diabetes are controlled by our genes. While researchers are eager to find out what other factors could contribute to this disease, a new study published by Yale researchers provides direct ...

Protein packaging may cause the immune attacks of type 1 diabetes

November 21, 2016
Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Recommended for you

New type 1 diabetes therapy shows promise for long-term reversal in both humans, dogs

August 21, 2018
What if instead of daily insulin injections or wearing pumps, just getting a shot every few months could reverse Type 1 diabetes for you—or your dog?

Poor sleep + type 2 diabetes = Slower wound healing

August 20, 2018
People with Type 2 diabetes who don't sleep well could need more time to heal their wounds, according to a new study published by researchers from the University of Tennessee, Knoxville.

Low levels of vitamin D3 and periodontitis may trigger the onset of Type 2 diabetes

August 20, 2018
In a rare study of its kind, new University of Toronto research has identified how vitamin D3 and periodontitis influence Type 2 diabetes.

Using mushrooms as a prebiotic may help improve glucose regulation

August 16, 2018
Eating white button mushrooms can create subtle shifts in the microbial community in the gut, which could improve the regulation of glucose in the liver, according to a team of researchers. They also suggest that better understanding ...

Cardiovascular disease related to type 2 diabetes can be reduced significantly

August 16, 2018
Properly composed treatment and refraining from cigarette consumption can significantly reduce the risk of cardiovascular disease resulting from type 2 diabetes, according to a study published in the New England Journal of ...

Blood test may identify gestational diabetes risk in first trimester

August 16, 2018
A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants, according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.